# EDGAR Filing Document

**Accession Number:** 0001720725
**File Stem:** 0001193125-23-000336
**Filing Date:** 2023-1
**Character Count:** 7554
**Document Hash:** 80b9b8023a488fb6714ca3483df3e17c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-000336.hdr.sgml**: 20230103

**ACCESSION NUMBER**: 0001193125-23-000336

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230103

**DATE AS OF CHANGE**: 20230103

**EFFECTIVENESS DATE**: 20230103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Oyster Point Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001720725
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 811030955
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-258498
- **FILM NUMBER:** 23500533

**BUSINESS ADDRESS:**
- **STREET 1:** 202 CARNEGIE CENTER
- **STREET 2:** SUITE 106
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
- **BUSINESS PHONE:** (609) 382-9032

**MAIL ADDRESS:**
- **STREET 1:** 202 CARNEGIE CENTER
- **STREET 2:** SUITE 106
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540

**As filed with the Securities and Exchange Commission on January 3, 2023** 

**Registration No. 333-234416** 

**Registration No. 333-254936** 

**Registration No. 333-258498** 

**Registration No. 333-262291** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-234416** 

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-254936** 

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-258498** 

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-262291** 

***UNDER***

***THE SECURITIES ACT OF 1933***

------

## Oyster Point Pharma, Inc.
**(Exact Name of Registrant as Specified in Its Charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **81-1030955** |
| **(State or Other Jurisdiction<br>of Incorporation or Organization)** | **(IRS Employer<br>Identification No.)** |
| **202 Carnegie Center, Suite 106**<br> **Princeton, New Jersey** | **08540** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Oyster Point Pharma, Inc. 2021 Inducement Plan** 

**Oyster Point Pharma, Inc. 2019 Equity Incentive Plan** 

**Oyster Point Pharma, Inc. 2019 Employee Stock Purchase Plan** 

**Oyster Point Pharma, Inc. 2016 Equity Incentive Plan** 

**(Full title of the plan)** 

------

**Jeffrey Nau, Ph.D., M.M.S.** 

**Chief Executive Officer** 

**Oyster Point Pharma, Inc.** 

**202 Carnegie Center, Suite 106** 

**Princeton, New Jersey 08540** 

**(609) 382-9032** 

**(Name, address and telephone number, including area code, of agent for service)** 

***With copies to:***

**Brandon Fenn** 

**Divakar Gupta** 

**Ian Nussbaum** 

**Cooley LLP** 

**55 Hudson Yards** 

**New York, New York 10001** 

**(212) 479-6000** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

------

**DEREGISTRATION OF SECURITIES** 

This Post-Effective Amendment relates to the following Registration Statements on Form S-8 (each, a "Registration Statement" and collectively, the "Registration Statements"), previously filed by Oyster Point Pharma, Inc., a Delaware corporation ("Oyster Point"), with the U.S. Securities and Exchange Commission (the "SEC"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on Form S-8 (File No. 333-234416), originally filed with the SEC on October 31, 2019, pertaining to the registration of 2,799,638 Shares of Oyster Point common stock, $0.001 par value (the "Shares"), under
Oyster Point's 2019 Equity Incentive Plan, 270,000 Shares under Oyster Point's 2019 Employee Stock Purchase Plan, and 2,752,846 Shares under Oyster Point's 2016 Equity Incentive Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on Form S-8 (File No. 333-254936), originally filed with the SEC on March 31, 2021, pertaining to the registration of 1,166,477 Shares under Oyster Point's 2019 Equity Incentive Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on Form S-8 (File No. 333-258498), originally filed with the SEC on August 5, 2021, pertaining to the registration of 650,000 Shares under Oyster Point's 2021 Inducement Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on Form S-8 (File No. 333-262291), originally filed with the SEC on January 21, 2022, pertaining to the registration of 1,070,967 Shares under Oyster Point's 2019 Equity Incentive Plan and 265,795 Shares under
Oyster Point's 2019 Employee Stock Purchase Plan.

On January 3, 2023, pursuant to that certain Agreement and Plan of Merger, dated as of November 7, 2022, by and among Oyster Point, Viatris Inc., a Delaware corporation ("Parent" or "Viatris"), and Iris Purchaser Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Oyster Point (the "Merger"), with Oyster Point surviving the Merger as a wholly owned subsidiary of Viatris.

As a result of the Merger, Oyster Point has terminated any and all offerings of Oyster Point's securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with undertakings made by Oyster Point in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold or not yet issued at the termination of the offering, Oyster Point hereby removes from registration all such securities of Oyster Point registered pursuant to the Registration Statements that remain unsold or not yet issued as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, Oyster Point certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the Borough of Princeton, State of New Jersey, on January 3, 2023.

---

| | | |
|:---|:---|:---|
|  | **OYSTER POINT PHARMA, INC.** | **OYSTER POINT PHARMA, INC.** |
| Date: January 3, 2023 | By: | /s/ Jeffrey Nau |
|  | Name: | Jeffrey Nau, Ph.D., M.M.S. |
|  | Title: | President and Chief Executive Officer |

---

No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.